Genetically Targeted Antifungal Therapeutics: A CRISPR-dCas9--RNAi Hybrid Framework with Dual-Gene Targeting, Evolutionary Escape Modeling, Bayesian Inference, Stochastic Simulations, and In Vitro/In Vivo Validation Protocols

This study delineates a state-of-the-art framework for Genetically Targeted Antifungal Therapeutics (GTAT), fusing CRISPR-dCas9 with RNAi for dual-gene silencing of \textit{ERG11} and \textit{FKS1} in \textit{Candida albicans}. The architecture integrates probabilistic evolutionary escape modeling via Poisson processes, Gillespie stochastic simulations incorporating fitness costs and population bottlenecks, and a hierarchical Bayesian framework for parameter inference on mRNA decay kinetics using numerical ODE solutions for enhanced mathematical precision. Synthetic data illustrate the model, yielding posterior means of bioavailability \(\hat{\phi} = 0.61\) (95\% HDI: [0.52, 0.70]) and silencing efficiency \(\hat{\eta} = 1.15~\mathrm{h}^{-1}\) (95\% HDI: [0.92, 1.38]), predicting 98.7\% knockdown at 12 hours (95\% HDI: [97.2\%, 99.4\%]). Limitations of synthetic data are transparently addressed, with detailed protocols for RT-qPCR in clinical isolates, cytotoxicity in HepG2/HEK293 cells, off-target RNA-seq, and extension to in vivo murine candidiasis models. The model further incorporates nuclease kinetics, macrophage clearance via Michaelis-Menten approximations, TLR-mediated immune modulation by PEGylated chitosan-lipid nanoparticles (CLNPs), and quantitative systems pharmacology (QSP) integration for translational PK/PD predictions. Dual-targeting suppresses escape probability from \(2.4 \times 10^{-3}\) to \(5.8 \times 10^{-6}\), with Gillespie simulations affirming resilience under varying population dynamics and selection pressures. Hypotheses are falsifiable, reproducible, and anchored in fungal genomics, systems pharmacology, evolutionary dynamics, and immunology, positioning GTAT as a paradigm-shifting platform for precision antimicrobials amid escalating resistance, informed by recent advances in CRISPR-Cas fungal applications and RNAi delivery.本研究构建了一套前沿的基因靶向抗真菌疗法（Genetically Targeted Antifungal Therapeutics, GTAT）框架，将CRISPR-dCas9与RNA干扰（RNA interference, RNAi）相结合，实现对白念珠菌（Candida albicans）中ERG11与FKS1基因的双重沉默。该架构整合了基于泊松过程的概率进化逃逸建模、纳入适合度成本与种群瓶颈的吉莱斯皮随机模拟，以及通过数值常微分方程求解以提升数学精度的、用于mRNA降解动力学参数推断的分层贝叶斯框架。合成数据对该模型进行了演示验证，得到生物利用度的后验均值为$hat{phi} = 0.61$（95%最高后验密度区间：[0.52, 0.70]），沉默效率为$hat{eta} = 1.15~mathrm{h}^{-1}$（95%最高后验密度区间：[0.92, 1.38]），并预测12小时时基因敲低效率可达98.7%（95%最高后验密度区间：[97.2%, 99.4%]）。研究透明化阐述了合成数据的局限性，并提供了针对临床分离株的实时定量荧光PCR（RT-qPCR）实验、HepG2/HEK293细胞毒性检测、脱靶RNA测序，以及拓展至体内小鼠念珠菌病模型的详细操作方案。该模型进一步整合了核酸酶动力学、基于米氏近似的巨噬细胞清除过程、聚乙二醇化壳聚糖脂质纳米颗粒（CLNPs）介导的Toll样受体（Toll-like Receptor, TLR）免疫调节，以及用于转化型药代动力学/药效动力学（Pharmacokinetics/Pharmacodynamics, PK/PD）预测的定量系统药理学（Quantitative Systems Pharmacology, QSP）集成模块。双重靶向策略将逃逸概率从$2.4 imes 10^{-3}$降至$5.8 imes 10^{-6}$，吉莱斯皮模拟证实了该框架在不同种群动态与选择压力下的鲁棒性。本研究提出的假设具备可证伪性与可重复性，且锚定真菌基因组学、系统药理学、进化动力学与免疫学领域，在不断升级的真菌耐药性背景下，结合CRISPR-Cas真菌应用与RNAi递送的最新进展，将GTAT打造为一款范式革新的精准抗菌疗法平台。